Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis
- 12 April 2017
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 56 (3) , 485-494
Abstract
Basal insulin controls primarily fasting plasma glucose but causes hypoglycaemia and weight gain, whilst glucagon like peptide 1 receptor agonists induce weight loss without increasing risk for hypoglycaemia. We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.Keywords
This publication has 18 references indexed in Scilit:
- IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin TherapyDiabetes Therapy, 2015
- One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trialDiabetes, Obesity and Metabolism, 2015
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balanceTherapeutic Advances in Endocrinology and Metabolism, 2015
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia, 2015
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetesThe Lancet Diabetes & Endocrinology, 2014
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)Diabetes Care, 2014
- Handling of Rescue and Missing Data Affects Synthesis and Interpretation of Evidence: The Sodium–Glucose Cotransporter 2 Inhibitor ExampleAnnals of Internal Medicine, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Barriers to insulin initiation and intensification and how to overcome themInternational Journal Of Clinical Practice, 2009
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986